Shanghai Haixin Group Co Ltd
SSE:600851
Shanghai Haixin Group Co Ltd
SSE:600851
Price:
7.81
CNY
0.13%
Market Closed
Market Cap:
¥5.8B
Relative Value
The Relative Value of one
Shanghai Haixin Group Co Ltd
stock under the Base Case scenario is
3.47
CNY.
Compared to the current market price of 7.81 CNY,
Shanghai Haixin Group Co Ltd
is
Overvalued by 56%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
3.47
CNY
Overvaluation 56%
Multiples Across Competitors
Competitors Multiples
Shanghai Haixin Group Co Ltd Competitors
Shanghai Haixin Group Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Shanghai Haixin Group Co Ltd
SSE:600851
|
5.8B CNY | 7.3 | 36.9 | 158.8 | 158.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD | 15.1 | 47.8 | 32.2 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.5 | 15 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.9B USD | 4.7 | 16.6 | 10.4 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP | 5.2 | 32.1 | 15.3 | 22.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.2 | 12.7 | 9.3 | 11 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.3B USD | 2.6 | 20.8 | 7.3 | 9.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
